A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
Phase: PHASE3
Conditions: Pruritus, Prurigo Nodularis
Sponsor: Vyne Therapeutics Inc.

Protocol: MTI-106 
Confidential - Proprietary Information 
 Protocol number: MTI-106. 
 Document title: A randomized, double-blind, placebo-controlled study of 
the efficacy, safety, and tolerability of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
 Version number: Protocol Version 4. 
 Date of the document: 16 December 2019. 
 NCT number: NCT03677401 

Abbreviated Clinical Study Report 
 
MTI-106 
16.1 Study Information 
CONFIDENTIAL 
 
Version 1.0 
16.1.1  
PROTOCOL AND PROTOCOL AMENDMENTS 
The following protocols under which subjects were enrolled and summaries of changes are 
provided: 
• Protocol Version 2.1 (02 July 2018) 
• Summary of Changes, Version 2.1 to 3.0 
• Protocol Version 3.0 (21 March 2019) 
• Summary of Changes, Version 3.0 to 4.0 
• Protocol Version 4.0 (16 December 2019) 
1

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 1 
CLINICAL STUDY PROTOCOL 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND 
TOLERABILITY OF SERLOPITANT FOR THE TREATMENT 
OF PRURITUS IN ADULTS WITH PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106   
Protocol Version/Date: 
Version 2.1/02 July 2018 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
 
 
 
Confidentiality Statement: 
This document is a confidential communication of Menlo Therapeutics Inc. As such, the 
recipients agree not to disclose or reproduce, without prior written approval, this document and 
any attachments, except to appropriate Ethics Committees, representatives of the US Food and 
Drug Administration, the European Medicines Agency, other Competent Authorities or 
regulatory agencies or as otherwise required by applicable laws or regulations.
2

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 2.1/02 July 2018   
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
3

Version 2.1/02 July 2018 
SIGNATURE PAGE FOR COORDINATING INVESTIGATOR 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Version 2.1/02 July 2018 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Coordinating Investigator’s printed name 
 
 
 
 
 
 
Coordinating Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
 
4

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
• 
Screening period: 2-4 weeks 
• 
Treatment period: 10 weeks 
• 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
6

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 200 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
7

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
8

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
• 
WI-NRS 4-point responder rate at Week 4 
• 
Change from baseline in WI-NRS to Day 7 
• 
Change from baseline in WI-NRS to Day 3 
• 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
Additional secondary efficacy endpoints are as follows: 
• 
Change from baseline in WI-NRS to other timepoints 
• 
WI-NRS 4-point responder rate at Week 2 
• 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
• 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
• 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
• 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
• 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
• 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 200 randomized and dosed subjects (100 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Two hundred subjects results in 90% power assuming a 
placebo responder rate of 
% and serlopitant rate of 
%. 
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
9
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 8 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit. Graphs of laboratory values 
over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
10

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS ..........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................12 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................24 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................28 
5.3 
Dosing Regimen...............................................................................................28 
11

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 10 
5.4 
Dose Modification ...........................................................................................28 
5.5 
Missed or Delayed Doses.................................................................................28 
5.6 
Study Drug Discontinuation ............................................................................28 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................29 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................29 
5.7.2 
Excluded Therapies ..............................................................................30 
5.7.3 
Rescue Therapies .................................................................................31 
5.8 
Assignment to Treatment .................................................................................31 
5.8.1 
Randomization .....................................................................................31 
5.8.2 
Blinding................................................................................................31 
5.9 
Treatment Compliance .....................................................................................32 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................32 
6.1 
Efficacy Parameters .........................................................................................32 
6.1.1 
Itch Numeric Rating Scale ...................................................................32 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................32 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................33 
6.1.4 
Dermatology Life Quality Index ..........................................................33 
6.1.5 
PN Photographs ...................................................................................33 
6.2 
Safety Parameters.............................................................................................33 
6.2.1 
Vital Signs ............................................................................................33 
6.2.2 
Physical Examination...........................................................................34 
6.2.3 
Clinical Laboratory Assessments .........................................................34 
6.2.4 
Electrocardiogram ................................................................................35 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................35 
6.2.6 
Epworth Sleepiness Scale ....................................................................35 
6.3 
Pharmacokinetic Measurements ......................................................................35 
6.4 
Subject Flow Diagram .....................................................................................35 
6.5 
Study Visits ......................................................................................................36 
6.5.1 
Screening Period ..................................................................................36 
6.5.2 
Screening Visit .....................................................................................37 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................38 
6.5.4 
Baseline Visit .......................................................................................39 
6.5.5 
Week 1 Telephone Contact Visit .........................................................40 
6.5.6 
Week 2 Visit ........................................................................................40 
6.5.7 
Week 4 Visit ........................................................................................41 
6.5.8 
Week 6 Visit ........................................................................................41 
6.5.9 
Week 10 Visit ......................................................................................42 
12

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................43 
6.5.11 
Early Termination ................................................................................44 
7 
ASSESSMENT OF SAFETY ................................................................................44 
7.1 
Definitions........................................................................................................44 
7.1.1 
Adverse Event ......................................................................................44 
7.1.2 
Serious Adverse Event .........................................................................45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................46 
7.1.4 
Deaths ..................................................................................................46 
7.1.5 
Pregnancies and Contraception Requirements for Females .................46 
7.1.6 
Worsening of Pruritus or PN................................................................47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............48 
7.2.1 
Adverse Event Reporting Period .........................................................48 
7.2.2 
Eliciting Adverse Events......................................................................48 
7.2.3 
Assessment of Severity ........................................................................48 
7.2.4 
Assessment of Causality ......................................................................49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................50 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................50 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................50 
7.6 
Emergency Unblinding ....................................................................................50 
8 
STATISTICAL METHODS ..................................................................................51 
8.1 
Decision Rule and Sample Size .......................................................................51 
8.2 
Handling of Missing Data ................................................................................52 
8.3 
Analysis Populations ........................................................................................53 
8.4 
Subject Disposition ..........................................................................................54 
8.5 
Subject Characteristics .....................................................................................54 
8.6 
Prior and Concomitant Medications ................................................................54 
8.7 
Treatment Compliance and Extent of Exposure ..............................................55 
8.8 
Efficacy Analyses ............................................................................................55 
8.8.1 
Primary Efficacy ..................................................................................55 
8.8.2 
Key Secondary Efficacy ......................................................................55 
8.8.3 
Additional Secondary Efficacy ............................................................56 
8.9 
Sensitivity Analyses .........................................................................................56 
8.9.1 
Last Observation Carried Forward.......................................................56 
8.9.2 
Repeated Measures Analysis ...............................................................56 
8.9.3 
Tipping Point Analysis ........................................................................56 
8.10 
Safety Analyses ................................................................................................56 
13

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................56 
8.10.2 
Clinical Safety Laboratory Results ......................................................57 
8.10.3 
Vital Signs ............................................................................................57 
8.10.4 
Electrocardiograms ..............................................................................57 
8.10.5 
Physical Exams ....................................................................................57 
8.10.6 
Menstrual Diaries .................................................................................57 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................57 
8.10.8 
Epworth Sleepiness Scale ....................................................................57 
8.11 
Population Pharmacokinetics Analysis ............................................................57 
9 
ADMINISTRATIVE ASPECTS ...........................................................................58 
9.1 
Changes to the Protocol ...................................................................................58 
9.2 
Study Termination ...........................................................................................58 
9.3 
Monitoring and Auditing Procedures...............................................................58 
9.4 
Transfer of Obligations ....................................................................................58 
9.5 
Informed Consent.............................................................................................59 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...59 
9.7 
Disclosure and Confidentiality ........................................................................59 
9.8 
Records and Electronic Case Report Forms ....................................................59 
9.9 
Good Clinical Practices and Ethical Study Conduct........................................60 
9.10 
End of Study Notification ................................................................................60 
9.11 
Publication of Results ......................................................................................60 
9.12 
Final Report .....................................................................................................60 
10 
REFERENCES ......................................................................................................61 
 
LIST OF APPENDICES 
Appendix A  Schedule of Activities and Assessments ..........................................................64 
Appendix B  List of Strong CYP3A4 Inhibitors ...................................................................66 
Appendix C  Worst Itch Numeric Rating Scale Questionnaire .............................................67 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity and Stage ..68 
Appendix E 
Dermatology Life Quality Index ......................................................................69 
Appendix F 
Hospital Anxiety and Depression Scale ...........................................................70 
Appendix G  Epworth Sleepiness Scale ................................................................................71 
 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................36 
 
14

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 13 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................49 
Table 2 
Schedule of Visit Activities .......................................................................64 
Table 3 
Schedule of eDiary Assessments ...............................................................65 
  
15

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
16

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
17

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
18

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
19

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant 
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
20

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
 M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
21
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
22

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
23

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
24

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 23 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
• WI-NRS 4-point responder rate at Week 4 
• Change from baseline in WI-NRS to Day 7 
• Change from baseline in WI-NRS to Day 3 
• Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 4-point responder rate at Week 2 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
25

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 24 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 200 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
26

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 25 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
27

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 26 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
28

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 27 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
29

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 28 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
30

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 29 
•
Discontinuation is deemed to be in the best interest of the subject, in the investigator’s
and/or Sponsor’s opinion, including evidence that the subject does not meet
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of
adherence to study procedures
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
31

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 30 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
32

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 31 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
33

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 32 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
34

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 33 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
35

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 34 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
36

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 35 
•
Additional optional studies will be supported through local procedural and/or laboratory
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the
investigator should discuss the need for such studies with the medical monitor during the
Screening period.
•
Standard cosyntropin stimulation testing should be performed on subjects with low
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and
relevant low corticotropin) results with the medical monitor.
6.2.4 
Electrocardiogram 
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
37

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 36 
Figure 1 
Subject Flow Diagram  
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
38

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 37 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
39

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 38 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
40

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 39 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
 
41

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 40 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
42

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 41 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
43

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 42 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
44

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 43 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
45

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 44 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
46

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 45 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
47

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 46 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths 
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
48

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 47 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
49

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 48 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
50

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 49 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
51

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 50 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
52

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 51 
8 
STATISTICAL METHODS 
All statistical processing will be performed using SAS® unless otherwise stated. No interim 
analyses are planned. Endpoints will be summarized with descriptive statistics by treatment 
group and visit. For continuous variables, the following information will be presented: 
n (number of subjects), mean, standard deviation, median, minimum and maximum. For 
categorical variables counts and percentages will be used. Summary statistics for imputed 
efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
then change from baseline to Day 7, and then Day 3, and finally the change from baseline to 
Week 10 in DLQI.  
The target sample size of 200 randomized and dosed subjects (100 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
A sample size of two hundred subjects results in 90% power assuming a placebo responder 
rate of 
% and serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
53
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 52 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. If any values are available, these will be used 
i.e. a minimum of 1 observation is required to compute a week’s average.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline d2 d3 d4 d5 d6 d7 week2 week3 week4 week5 week6 week7 week8 
week9 week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
54

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 53 
Missing Week 10 DLQI data will be derived for the analysis using the method of MCMC 
multiple imputation. The following steps will be followed: 
1. DLQI for Week 10 will be calculated as per scoring instructions.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing values in each dataset 
will be filled in using the MCMC method to generate 25 datasets. The resulting 
datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week4 week10; 
run; 
 
3. Each complete dataset will be analyzed as specified for the particular analysis. 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 4 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
55
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 54 
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80−120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
56

Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 55 
8.7 
Treatment Compliance and Extent of Exposure 
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in Section 8.2.  
8.8.2 
Key Secondary Efficacy 
The differences between treatment groups for the key secondary efficacy endpoint, Week 4 
WI-NRS 4-point responder rate, will be the CMH test identical to the one used for the 
primary endpoint.  
The remaining key secondary efficacy endpoints will be analyzed using an analysis of 
covariance (ANCOVA) model with treatment group and stratification factor as fixed effects and 
the respective baseline values as a covariate.  Both least squares means and observed means will 
be presented. 
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test. If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA. Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
57

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 56 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints will include analyses analogous to the primary and 
key secondary efficacy analyses. Additional secondary efficacy endpoints which may be 
drawn from the primary and key secondary imputations (including all WI-NRS endpoints) 
will be analyzed using the imputed data. Additional secondary efficacy endpoints otherwise 
will be analyzed using available data. P-values will be included for descriptive purposes 
only. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary/key secondary efficacy endpoints will each be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
The remaining key secondary efficacy variables will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
58

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 57 
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit. Graphs of laboratory values over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
59

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 58 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
• Study design or conduct 
• Willingness of a subject to participate in the study 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
60

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 59 
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
61

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 60 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
62

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 61 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
63

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 62 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
64

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 63 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
65

Menlo Therapeutics Inc 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 64 
APPENDIX A 
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
Informed consent 
X 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
HADS, ESS 
X 
X 
X 
X 
X 
ECG 
X 
X 
X 
X 
X 
X 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
Physical exam4 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medications  
X 
X 
X 
X 
X 
X 
X 
X 
Labs5 
X 
X 
X 
X 
X 
Urine pregnancy test6 
X 
X 
X 
 X 
X 
X 
X 
PK blood draw  
X 
X 
X 
Review of I/E criteria 
X 
X 
X 
IGA PN-A and IGA PN-S 
X 
X 
X 
X 
X 
X 
Photography (selected sites) 
X 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
X  
X 
eDiary review/compliance7 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense and/or collect study drug 
X 
X 
X 
X 
X 
X 
Review study drug compliance 
X 
X 
X 
X 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
66

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 65 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
67

Menlo Therapeutics Inc 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 66 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1.
boceprevir
2.
clarithromycin
3.
cobicistat
4.
conivaptan
5.
danoprevir and ritonavir
6.
diltiazem
7.
elvitegravir and ritonavir
8.
idelalisib
9.
indinavir and ritonavir
10.
itraconazolea
11.
ketoconazolea
12.
lopinavir and ritonavir
13.
nefazodone
14.
nelfinavir
15.
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir)
16.
posaconazolea
17.
ritonavir
18.
saquinavir and ritonavir
19.
telaprevir
20.
tipranavir and ritonavir
21.
troleandomycin
22.
voriconazolea
23.
regular grapefruit juice consumption (note: The effect of grapefruit juice varies
widely among brands and is concentration-, dose-, and preparation-dependent.
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the
preparation)b
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
68

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 67 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
69

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 68 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
70

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 69 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
71

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 70 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
72

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 71 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
73

 
1 
CLINICAL STUDY PROTOCOL MTI-106 
SUMMARY OF CHANGES 
 
Drug Product Name: 
Serlopitant 
 
Study Title:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
 
IND No.: 
 
 
117780 
EudraCT No.:  
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol Version: 
 
3.0 
Protocol Date: 
 
21 March 2019 
Replaces Version/Date: 
2.1 / 02 July 2018 
 
74

Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 2.1 to Version 3.0 
 
 
 
2 
The following changes were made to the MTI-106 Clinical Study Protocol from Version 2.1 to Version 3.0. 
KEY CHANGES: 
Section(s) 
Summary of Change 
Reason for Change 
Protocol Synopsis  
Updated consistent with changes to the protocol body. 
Ensure consistency between synopsis and protocol 
body.  
8.8.2 Key 
Secondary Efficacy; 
8.9.2 Repeated 
Measures Analysis 
Removed two key secondary efficacy endpoints 
These secondary efficacy endpoints were unnecessary 
for evaluation of the study drug. 
4.1 Study 
Population 
Increased study population to 280 subjects 
In completed Phase 2 pruritus studies, with variations 
in screening methodologies, placebo responder rates 
have varied between 
% and 
% and serlopitant 
rates between 
% and 
%. The sample size was 
recalculated as a result of this observation. 
8. Statistical 
methods; 8.11 
Interim Analyses 
Added optional interim analysis 
An interim analysis may be performed to assess the 
adequacy of the sample size assumptions. 
8.1 Decision Rule 
and Sample Size 
Removed two key secondary efficacy endpoints, increased 
sample size 
Please see comments for section 4.1 and 8/8.1. 
 
8.2 Statistical 
methods 
Updated Syntax to replace individual day calculations with 
week 1 calculation 
Correction as key secondary endpoints were removed. 
 
ADMINISTRATIVE CHANGES: 
Section(s) 
Summary of Change 
Title page 
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Signature Page for Investigator(s)   
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Sponsor Protocol Approval Signature(s) 
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Table of Contents 
Updated  
75
CCI
CCI
CCI
CCI

Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 2.1 to Version 3.0 
 
 
 
3 
Throughout  
Updated protocol version in footer; Edited formatting and corrected minor typos and 
inconsistencies 
 
76

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 3.0/21 March 2019 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 3.0/21 March 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
78

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 3.0/21 March 2019 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
 
Screening period: 2-4 weeks 
 
Treatment period: 10 weeks 
 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
80

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 280 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
81

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
82

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
 
WI-NRS 4-point responder rate at Week 4 
 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
Additional secondary efficacy endpoints are as follows: 
 
Change from baseline in WI-NRS to other timepoints 
 
WI-NRS 4-point responder rate at Week 2 
 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 280 randomized and dosed subjects (140 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Completed Phase 2 studies indicate that placebo responder 
rates vary between 
% and 
% and serlopitant rates between 
% and 
%. 
A sample size of 280 subjects provides >90% power assuming a placebo 
responder rate of 
% and a serlopitant rate of 
%.  
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
83
CCI
CCI
CCI
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 8 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit. Graphs of laboratory values 
over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
84

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS...........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................12 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................23 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................27 
5.3 
Dosing Regimen...............................................................................................27 
85

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 10 
5.4 
Dose Modification ...........................................................................................27 
5.5 
Missed or Delayed Doses.................................................................................27 
5.6 
Study Drug Discontinuation ............................................................................27 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................28 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................28 
5.7.2 
Excluded Therapies ..............................................................................29 
5.7.3 
Rescue Therapies .................................................................................30 
5.8 
Assignment to Treatment .................................................................................30 
5.8.1 
Randomization .....................................................................................30 
5.8.2 
Blinding................................................................................................30 
5.9 
Treatment Compliance .....................................................................................31 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................31 
6.1 
Efficacy Parameters .........................................................................................31 
6.1.1 
Itch Numeric Rating Scale ...................................................................31 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................31 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................32 
6.1.4 
Dermatology Life Quality Index ..........................................................32 
6.1.5 
PN Photographs ...................................................................................32 
6.2 
Safety Parameters .............................................................................................32 
6.2.1 
Vital Signs ............................................................................................32 
6.2.2 
Physical Examination...........................................................................33 
6.2.3 
Clinical Laboratory Assessments .........................................................33 
6.2.4 
Electrocardiogram ................................................................................34 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................34 
6.2.6 
Epworth Sleepiness Scale ....................................................................34 
6.3 
Pharmacokinetic Measurements ......................................................................34 
6.4 
Subject Flow Diagram .....................................................................................34 
6.5 
Study Visits ......................................................................................................35 
6.5.1 
Screening Period ..................................................................................35 
6.5.2 
Screening Visit .....................................................................................36 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................37 
6.5.4 
Baseline Visit .......................................................................................38 
6.5.5 
Week 1 Telephone Contact Visit .........................................................39 
6.5.6 
Week 2 Visit ........................................................................................39 
6.5.7 
Week 4 Visit ........................................................................................40 
6.5.8 
Week 6 Visit ........................................................................................40 
6.5.9 
Week 10 Visit ......................................................................................41 
86

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................42 
6.5.11 
Early Termination ................................................................................43 
7 
ASSESSMENT OF SAFETY ................................................................................43 
7.1 
Definitions........................................................................................................43 
7.1.1 
Adverse Event ......................................................................................43 
7.1.2 
Serious Adverse Event .........................................................................44 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................45 
7.1.4 
Deaths ..................................................................................................45 
7.1.5 
Pregnancies and Contraception Requirements for Females .................45 
7.1.6 
Worsening of Pruritus or PN................................................................46 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............47 
7.2.1 
Adverse Event Reporting Period .........................................................47 
7.2.2 
Eliciting Adverse Events ......................................................................47 
7.2.3 
Assessment of Severity ........................................................................47 
7.2.4 
Assessment of Causality ......................................................................48 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................49 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................49 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................49 
7.6 
Emergency Unblinding ....................................................................................49 
8 
STATISTICAL METHODS ..................................................................................50 
8.1 
Decision Rule and Sample Size .......................................................................50 
8.2 
Handling of Missing Data ................................................................................51 
8.3 
Analysis Populations ........................................................................................52 
8.4 
Subject Disposition ..........................................................................................53 
8.5 
Subject Characteristics .....................................................................................53 
8.6 
Prior and Concomitant Medications ................................................................53 
8.7 
Treatment Compliance and Extent of Exposure ..............................................54 
8.8 
Efficacy Analyses ............................................................................................54 
8.8.1 
Primary Efficacy ..................................................................................54 
8.8.2 
Key Secondary Efficacy ......................................................................54 
8.8.3 
Additional Secondary Efficacy ............................................................55 
8.9 
Sensitivity Analyses .........................................................................................55 
8.9.1 
Last Observation Carried Forward.......................................................55 
8.9.2 
Repeated Measures Analysis ...............................................................55 
8.9.3 
Tipping Point Analysis ........................................................................55 
8.10 
Safety Analyses ................................................................................................55 
87

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................55 
8.10.2 
Clinical Safety Laboratory Results ......................................................56 
8.10.3 
Vital Signs ............................................................................................56 
8.10.4 
Electrocardiograms ..............................................................................56 
8.10.5 
Physical Exams ....................................................................................56 
8.10.6 
Menstrual Diaries .................................................................................56 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................56 
8.10.8 
Epworth Sleepiness Scale ....................................................................56 
8.11 
Interim Analyses ..............................................................................................56 
8.12 
Population Pharmacokinetics Analysis ............................................................57 
9 
ADMINISTRATIVE ASPECTS ...........................................................................57 
9.1 
Changes to the Protocol ...................................................................................57 
9.2 
Study Termination ...........................................................................................57 
9.3 
Monitoring and Auditing Procedures...............................................................57 
9.4 
Transfer of Obligations ....................................................................................58 
9.5 
Informed Consent.............................................................................................58 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...58 
9.7 
Disclosure and Confidentiality ........................................................................58 
9.8 
Records and Electronic Case Report Forms ....................................................59 
9.9 
Good Clinical Practices and Ethical Study Conduct ........................................59 
9.10 
End of Study Notification ................................................................................59 
9.11 
Publication of Results ......................................................................................59 
9.12 
Final Report .....................................................................................................60 
10 
REFERENCES ......................................................................................................61 
 
LIST OF APPENDICES 
Appendix A  
Schedule of Activities and Assessments ..............................................64 
Appendix B  
List of Strong CYP3A4 Inhibitors .......................................................66 
Appendix C  
Worst Itch Numeric Rating Scale Questionnaire .................................67 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity 
and Stage ..........................................................................................................68 
Appendix E 
Dermatology Life Quality Index ..........................................................69 
Appendix F 
Hospital Anxiety and Depression Scale ...............................................70 
Appendix G  
Epworth Sleepiness Scale ....................................................................71 
 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................35 
 
88

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 13 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................48 
Table 2 
Schedule of Visit Activities .......................................................................64 
Table 3 
Schedule of eDiary Assessments ...............................................................65 
  
89

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
90

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
91

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
92

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
93

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant  
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
94

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
, M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
95
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
96

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
97

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
98

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 23 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
 WI-NRS 4-point responder rate at Week 4 
 Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 4-point responder rate at Week 2 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
99

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 24 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 280 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
100

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 25 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
101

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 26 
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
102

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 27 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
103

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 28 
• Discontinuation is deemed to be in the best interest of the subject, in the investigator’s 
and/or Sponsor’s opinion, including evidence that the subject does not meet 
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of 
adherence to study procedures 
 
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
104

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 29 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
105

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 30 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
106

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 31 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
107

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 32 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
108

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 33 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
109

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 34 
• Additional optional studies will be supported through local procedural and/or laboratory 
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea 
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the 
investigator should discuss the need for such studies with the medical monitor during the 
Screening period. 
• Standard cosyntropin stimulation testing should be performed on subjects with low 
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and 
relevant low corticotropin) results with the medical monitor. 
6.2.4 
Electrocardiogram  
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
110

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 35 
Figure 1 
Subject Flow Diagram   
   
 
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 36 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
112

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 37 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
113

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 38 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
 
114

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 39 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
115

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 40 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
116

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 41 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
117

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 42 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
118

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 43 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
119

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 44 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
120

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and Electrocardiogram 
Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths  
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
121

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 46 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
122

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
123

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 48 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
124

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
125

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 50 
8 
STATISTICAL METHODS  
All statistical processing will be performed using SAS® unless otherwise stated. One interim 
analysis may be performed. Endpoints will be summarized with descriptive statistics by 
treatment group and visit. For continuous variables, the following information will be 
presented: n (number of subjects), mean, standard deviation, median, minimum and 
maximum. For categorical variables counts and percentages will be used. Summary statistics 
for imputed efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
and then the change from baseline to Week 10 in DLQI.  
The target sample size of 280 randomized and dosed subjects (140 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
Completed Phase 2 studies indicate that placebo responder rates vary between 
% and 
% 
and serlopitant rates between 
% and 
%. A sample size of 280 subjects provides >90% 
power assuming a placebo responder rate of 
% and a serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
126
CCI
CCI
CCI
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 51 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. If any values are available, these will be used 
i.e. a minimum of 1 observation is required to compute a week’s average.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week1 week2 week3 week4 week5 week6 week7 week8 week9 
week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
127

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 52 
Missing Week 10 DLQI data will be derived for the analysis using the method of MCMC 
multiple imputation. The following steps will be followed: 
1. DLQI for Week 10 will be calculated as per scoring instructions.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing values in each dataset 
will be filled in using the MCMC method to generate 25 datasets. The resulting 
datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week4 week10; 
run; 
 
3. Each complete dataset will be analyzed as specified for the particular analysis. 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 4 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
128
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 53 
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
129

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 54 
8.7 
Treatment Compliance and Extent of Exposure  
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in 
Section 8.2.  
8.8.2 
Key Secondary Efficacy  
The differences between treatment groups for the key secondary efficacy endpoint, Week 4 
WI-NRS 4-point responder rate, will be the CMH test identical to the one used for the 
primary endpoint.  
Change from baseline in DLQI to Week 10 will be analyzed using an analysis of covariance 
(ANCOVA) model with treatment group and stratification factor as fixed effects and the baseline 
DLQI as a covariate.  Both least squares means and observed means will be presented. 
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test. If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA. Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
130

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 55 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints will include analyses analogous to the primary and 
key secondary efficacy analyses. Additional secondary efficacy endpoints which may be 
drawn from the primary and key secondary imputations (including all WI-NRS endpoints) 
will be analyzed using the imputed data. Additional secondary efficacy endpoints otherwise 
will be analyzed using available data. P-values will be included for descriptive purposes 
only. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary and key secondary WI-NRS endpoints will be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
Change from baseline in DLQI to Week 10 will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
131

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 56 
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit. Graphs of laboratory values over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Interim Analyses  
An interim analysis may be performed once approximately 50% of subjects have available 
Week 10 efficacy assessments. The purpose of this is to assess the adequacy of the sample 
size assumptions. In order to maintain the integrity of the trial, no unblinding of investigators 
or Sponsor will occur. The interim analysis will be performed by an independent statistician. 
132

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 57 
No decrease in sample size will be considered; only an increase in sample size may be 
considered. Full details would be provided in a separate Interim Analysis Plan. 
8.12 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
• Study design or conduct 
• Willingness of a subject to participate in the study 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
133

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 58 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
134

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 59 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
135

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 60 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
136

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 61 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
137

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 62 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
138

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 63 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
139

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 64 
APPENDIX A  
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
DLQI 
 
 
X 
 
 
X 
 
X 
 
X 
HADS, ESS 
 
 
X 
 
 
X 
 
X 
X 
X 
ECG 
X 
 
 
 
X 
X 
 
X 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
 
 
 
 
 
 
 
Physical exam4 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Concomitant medications  
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Labs5  
X 
 
 
 
X 
 
  
X 
X 
X 
Urine pregnancy test6 
X 
 
X 
 
 
X 
 X 
X 
X 
X 
PK blood draw  
 
 
 
 
X 
X 
 
X 
 
 
Review of I/E criteria 
X 
X 
X 
 
 
 
 
 
 
 
IGA PN-A and IGA PN-S 
 
 
X 
 
X 
X 
 
X 
X 
X 
Photography (selected sites) 
 
 
X 
 
 
 
 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
 
 
 
  
 
 
 
X  
X 
eDiary review/compliance7 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispense and/or collect study drug 
 
 
X 
 
X 
X 
X 
X 
 
X 
Review study drug compliance 
 
 
 
 
X 
X 
X 
X 
 
 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
140

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 65 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
141

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 66 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1. 
boceprevir 
2. 
clarithromycin 
3. 
cobicistat 
4. 
conivaptan 
5. 
danoprevir and ritonavir 
6. 
diltiazem 
7. 
elvitegravir and ritonavir 
8. 
idelalisib 
9. 
indinavir and ritonavir 
10. 
itraconazolea 
11. 
ketoconazolea 
12. 
lopinavir and ritonavir 
13. 
nefazodone 
14. 
nelfinavir 
15. 
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir) 
16. 
posaconazolea 
17. 
ritonavir 
18. 
saquinavir and ritonavir 
19. 
telaprevir 
20. 
tipranavir and ritonavir 
21. 
troleandomycin 
22. 
voriconazolea 
23. 
regular grapefruit juice consumption (note: The effect of grapefruit juice varies 
widely among brands and is concentration-, dose-, and preparation-dependent. 
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the 
preparation)b 
 
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
 
142

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 67 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
   
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
143

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 68 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
144

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 69 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 70 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 71 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
  
 
  
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
147

 
1 
CLINICAL STUDY PROTOCOL MTI-106 
SUMMARY OF CHANGES 
 
Drug Product Name: 
Serlopitant 
 
Study Title:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
 
IND No.: 
 
 
117780 
EudraCT No.:  
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol Version: 
 
4.0 
Protocol Date: 
 
16 Dec 2019 
Replaces Version/Date: 
3.0 / 21 March 2019 
 
148

Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 3.0 to Version 4.0 
 
 
 
2 
The following changes were made to the MTI-106 Clinical Study Protocol from Version 3.0 to Version 4.0. 
KEY CHANGES: 
Section(s) 
Summary of Change 
Reason for Change 
Protocol Synopsis  
Updated consistent with changes to the protocol body. 
Ensure consistency between synopsis and protocol 
body.  
3.3.2 Key 
Secondary Efficacy 
Endpoints 
Removed ‘Change from Baseline in Dermatology Life 
Quality Index (DLQI) to Week 10’  
 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
 As a mixed tool consisting of 10 questions, not all of 
which are specific to subjects with pruritus, the DLQI 
may have limited utility in the subject population. It is 
therefore removed from the multiplicity testing strategy 
as a Key Secondary Efficacy Endpoint, however is still 
retained as an Additional Secondary Efficacy Endpoint 
to enable an evaluation of the potential improvement in 
quality of life (see below). 
 
An improvement in pruritus (>4-point reduction in WI-
NRS) may be realized as early as  Week 2 of treatment 
and therefore is added as a Key Secondary Efficacy 
Endpoint and included in the multiplicity testing 
strategy. 
3.3.3 Additional 
Secondary Efficacy 
Endpoints’ 
Removed ‘WI-NRS 4-point responder rate at Week 2’ 
Added ‘Change from Baseline in DLQI to Week 10’  
Added ‘Change from Baseline in DLQI Question 1 to 
Week 10’    
Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints, and retains ability to 
evaluate DLQI as an Additional Secondary Efficacy 
Endpoint 
Update due to prior change in SAP to analyze most 
relevant DLQI question as an additional secondary 
efficacy endpoint 
8.1 Decision Rule 
and Sample Size  
Removed ‘Change from Baseline in DLQI to Week 10’ 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints. 
8.2 Handling of 
Missing Data 
Changed the minimum number of observations needed to 
compute a week’s average of WI-NRS from 1 observation 
to 4 observations. 
Removed the explanation for handling missing Week 10 
DLQI data. 
A requirement to use a minimum of 4 observations 
collected over the course of a week will better support 
computing a week’s average for the WI-NRS, instead 
of allowing for use of a single data point. 
149

Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 3.0 to Version 4.0 
 
 
 
3 
Section(s) 
Summary of Change 
Reason for Change 
Updated the number of random seeds needed to impute 
missing data. 
8.8.2 Key 
Secondary Efficacy 
Removed ‘Change from Baseline in DLQI to Week 10’ 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
Removed information regarding the ANCOVA model 
 Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints. 
8.8.3 Additional 
Secondary Efficacy 
Added information regarding the analysis of the secondary 
endpoints 
Aligns with changes made to 3.3.3 Additional 
Secondary Endpoints 
8.10.2 Clinical 
Safety Laboratory 
Results 
Removed ‘Graphs of laboratory values over time will also 
be produced.’ 
Update due to prior change in SAP  
 
ADMINISTRATIVE CHANGES: 
Section(s) 
Summary of Change 
Title page 
Added protocol version number and release date  
Signature Page for Investigator(s)   
Added protocol version number and release date 
Sponsor Protocol Approval Signature(s) 
Added protocol version number and release date  
Throughout  
Updated protocol version in footer; Edited formatting and corrected minor typos and 
inconsistencies 
 
150

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 1 
CLINICAL STUDY PROTOCOL 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND 
TOLERABILITY OF SERLOPITANT FOR THE TREATMENT 
OF PRURITUS IN ADULTS WITH PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106   
Protocol Version/Date: 
Version 4.0/16 December 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
 
 
 
Confidentiality Statement: 
This document is a confidential communication of Menlo Therapeutics Inc. As such, the 
recipients agree not to disclose or reproduce, without prior written approval, this document and 
any attachments, except to appropriate Ethics Committees, representatives of the US Food and 
Drug Administration, the European Medicines Agency, other Competent Authorities or 
regulatory agencies or as otherwise required by applicable laws or regulations.
151

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 4.0/16 December 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
152

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
• 
Screening period: 2-4 weeks 
• 
Treatment period: 10 weeks 
• 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
154

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 280 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
155

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
156

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
• 
WI-NRS 4-point responder rate at Week 4 
• 
WI-NRS 4-point responder rate at Week 2 
Additional secondary efficacy endpoints are as follows: 
• 
Change from baseline in WI-NRS to other timepoints 
• 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
• 
Change from baseline in DLQI Question 1 to Week 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
• 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
• 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
• 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
• 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
• 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 280 randomized and dosed subjects (140 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Completed Phase 2 studies indicate that placebo responder 
rates vary between 
% and 
% and serlopitant rates between 
% and 
%. 
A sample size of 280 subjects provides >90% power assuming a placebo 
responder rate of 
% and a serlopitant rate of 
%.  
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
157
CCI
CCI
CCI
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 8 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
158

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS...........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................13 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................24 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................27 
5.3 
Dosing Regimen...............................................................................................27 
159

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 10 
5.4 
Dose Modification ...........................................................................................27 
5.5 
Missed or Delayed Doses.................................................................................27 
5.6 
Study Drug Discontinuation ............................................................................27 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................28 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................28 
5.7.2 
Excluded Therapies ..............................................................................29 
5.7.3 
Rescue Therapies .................................................................................30 
5.8 
Assignment to Treatment .................................................................................30 
5.8.1 
Randomization .....................................................................................30 
5.8.2 
Blinding................................................................................................30 
5.9 
Treatment Compliance .....................................................................................31 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................31 
6.1 
Efficacy Parameters .........................................................................................31 
6.1.1 
Itch Numeric Rating Scale ...................................................................31 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................31 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................32 
6.1.4 
Dermatology Life Quality Index ..........................................................32 
6.1.5 
PN Photographs ...................................................................................32 
6.2 
Safety Parameters .............................................................................................32 
6.2.1 
Vital Signs ............................................................................................32 
6.2.2 
Physical Examination...........................................................................33 
6.2.3 
Clinical Laboratory Assessments .........................................................33 
6.2.4 
Electrocardiogram ................................................................................34 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................34 
6.2.6 
Epworth Sleepiness Scale ....................................................................34 
6.3 
Pharmacokinetic Measurements ......................................................................34 
6.4 
Subject Flow Diagram .....................................................................................35 
6.5 
Study Visits ......................................................................................................35 
6.5.1 
Screening Period ..................................................................................36 
6.5.2 
Screening Visit .....................................................................................36 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................37 
6.5.4 
Baseline Visit .......................................................................................38 
6.5.5 
Week 1 Telephone Contact Visit .........................................................39 
6.5.6 
Week 2 Visit ........................................................................................39 
6.5.7 
Week 4 Visit ........................................................................................40 
6.5.8 
Week 6 Visit ........................................................................................40 
6.5.9 
Week 10 Visit ......................................................................................41 
160

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................42 
6.5.11 
Early Termination ................................................................................43 
7 
ASSESSMENT OF SAFETY ................................................................................43 
7.1 
Definitions........................................................................................................43 
7.1.1 
Adverse Event ......................................................................................43 
7.1.2 
Serious Adverse Event .........................................................................44 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................45 
7.1.4 
Deaths ..................................................................................................45 
7.1.5 
Pregnancies and Contraception Requirements for Females .................45 
7.1.6 
Worsening of Pruritus or PN................................................................46 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............47 
7.2.1 
Adverse Event Reporting Period .........................................................47 
7.2.2 
Eliciting Adverse Events ......................................................................47 
7.2.3 
Assessment of Severity ........................................................................47 
7.2.4 
Assessment of Causality ......................................................................48 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................49 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................49 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................49 
7.6 
Emergency Unblinding ....................................................................................49 
8 
STATISTICAL METHODS ..................................................................................50 
8.1 
Decision Rule and Sample Size .......................................................................50 
8.2 
Handling of Missing Data ................................................................................51 
8.3 
Analysis Populations ........................................................................................52 
8.4 
Subject Disposition ..........................................................................................53 
8.5 
Subject Characteristics .....................................................................................53 
8.6 
Prior and Concomitant Medications ................................................................53 
8.7 
Treatment Compliance and Extent of Exposure ..............................................53 
8.8 
Efficacy Analyses ............................................................................................53 
8.8.1 
Primary Efficacy ..................................................................................53 
8.8.2 
Key Secondary Efficacy ......................................................................54 
8.8.3 
Additional Secondary Efficacy ............................................................54 
8.9 
Sensitivity Analyses .........................................................................................54 
8.9.1 
Last Observation Carried Forward.......................................................54 
8.9.2 
Repeated Measures Analysis ...............................................................54 
8.9.3 
Tipping Point Analysis ........................................................................55 
8.10 
Safety Analyses ................................................................................................55 
161

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................55 
8.10.2 
Clinical Safety Laboratory Results ......................................................55 
8.10.3 
Vital Signs ............................................................................................55 
8.10.4 
Electrocardiograms ..............................................................................55 
8.10.5 
Physical Exams ....................................................................................56 
8.10.6 
Menstrual Diaries .................................................................................56 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................56 
8.10.8 
Epworth Sleepiness Scale ....................................................................56 
8.11 
Interim Analyses ..............................................................................................56 
8.12 
Population Pharmacokinetics Analysis ............................................................56 
9 
ADMINISTRATIVE ASPECTS ...........................................................................56 
9.1 
Changes to the Protocol ...................................................................................56 
9.2 
Study Termination ...........................................................................................57 
9.3 
Monitoring and Auditing Procedures...............................................................57 
9.4 
Transfer of Obligations ....................................................................................57 
9.5 
Informed Consent.............................................................................................57 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...57 
9.7 
Disclosure and Confidentiality ........................................................................58 
9.8 
Records and Electronic Case Report Forms ....................................................58 
9.9 
Good Clinical Practices and Ethical Study Conduct ........................................59 
9.10 
End of Study Notification ................................................................................59 
9.11 
Publication of Results ......................................................................................59 
9.12 
Final Report .....................................................................................................59 
10 
REFERENCES ......................................................................................................60 
 
LIST OF APPENDICES 
Appendix A  
Schedule of Activities and Assessments ..............................................63 
Appendix B  
List of Strong CYP3A4 Inhibitors .......................................................65 
Appendix C  
Worst Itch Numeric Rating Scale Questionnaire .................................66 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity 
and Stage ..........................................................................................................67 
Appendix E 
Dermatology Life Quality Index ..........................................................68 
Appendix F 
Hospital Anxiety and Depression Scale ...............................................69 
Appendix G  
Epworth Sleepiness Scale ....................................................................70 
 
162

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 13 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................35 
 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................48 
Table 2 
Schedule of Visit Activities .......................................................................63 
Table 3 
Schedule of eDiary Assessments ...............................................................64 
  
163

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
164

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
165

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
166

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
167

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant  
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
168

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
, M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
169
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
170

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
171

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
172

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 23 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
• WI-NRS 4-point responder rate at Week 4 
• WI-NRS 4-point responder rate at Week 2 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
• Change from baseline in DLQI Question 1 to Week 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
173

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 24 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 280 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
174

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 25 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
175

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 26 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
176

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 27 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
177

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 28 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
• Discontinuation is deemed to be in the best interest of the subject, in the investigator’s 
and/or Sponsor’s opinion, including evidence that the subject does not meet 
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of 
adherence to study procedures 
 
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
178

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 29 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
179

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 30 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
180

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 31 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
181

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 32 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
182

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 33 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
183

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 34 
• Additional optional studies will be supported through local procedural and/or laboratory 
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea 
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the 
investigator should discuss the need for such studies with the medical monitor during the 
Screening period. 
• Standard cosyntropin stimulation testing should be performed on subjects with low 
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and 
relevant low corticotropin) results with the medical monitor. 
 
6.2.4 
Electrocardiogram  
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
184

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 35 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
Figure 1 
Subject Flow Diagram   
   
 
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
185

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 36 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
186

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 37 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
187

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 38 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
188

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 39 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
189

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 40 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
190

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 41 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
191

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 42 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
192

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 43 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
193

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 44 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
194

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and Electrocardiogram 
Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths  
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
195

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 46 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
196

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
197

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 48 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
198

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
199

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 50 
8 
STATISTICAL METHODS  
All statistical processing will be performed using SAS® unless otherwise stated. One interim 
analysis may be performed. Endpoints will be summarized with descriptive statistics by 
treatment group and visit. For continuous variables, the following information will be 
presented: n (number of subjects), mean, standard deviation, median, minimum and 
maximum. For categorical variables counts and percentages will be used. Summary statistics 
for imputed efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
and then the Week 2 WI-NRS 4-point responder rate.  
The target sample size of 280 randomized and dosed subjects (140 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
Completed Phase 2 studies indicate that placebo responder rates vary between 
% and 
% 
and serlopitant rates between 
% and 
%. A sample size of 280 subjects provides >90% 
power assuming a placebo responder rate of 
% and a serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
200
CCI
CCI
CCI
CCI
CCI
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 51 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. In order to compute a week’s average, a 
minimum of 4 values must be available for that week. The weekly average will be 
imputed when there are fewer than 4 values available.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week1 week2 week3 week4 week5 week6 week7 week8 week9 
week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
201

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 52 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 2 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
  
 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80−120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
202
CCI

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 53 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
8.7 
Treatment Compliance and Extent of Exposure  
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in 
Section 8.2.  
203

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 54 
8.8.2 
Key Secondary Efficacy  
The differences between treatment groups for the key secondary efficacy endpoints, Week 2 WI-
NRS 4-point responder rate and Week 4 WI-NRS 4-point responder rate, will be the CMH test 
identical to the one used for the primary endpoint.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints which may be drawn from the primary and key 
secondary imputations (including all WI-NRS endpoints) will be analyzed using the imputed 
data. Additional secondary efficacy endpoints otherwise will be analyzed using available 
data. P-values will be included for descriptive purposes only. 
Additional secondary efficacy endpoints which are dichotomous (responder) will include 
analyses analogous to the primary and key secondary efficacy analyses.  
Additional secondary efficacy endpoints based on change from baseline will be analyzed 
using an analysis of covariance (ANCOVA) model with treatment group and stratification 
factor as fixed effects and the baseline value as a covariate. Both least squares means and 
observed means will be presented.  
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test.  If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA.  Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary and key secondary WI-NRS endpoints will be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
204

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 55 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
Change from baseline in DLQI to Week 10 will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
205

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 56 
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Interim Analyses  
No interim analysis is planned.  
8.12 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
206

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 57 
• Study design or conduct 
• Willingness of a subject to participate in the study 
 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
207

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 58 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
208

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 59 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
209

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 60 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
210

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 61 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
211

Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 62 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
212

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 63 
APPENDIX A  
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
DLQI 
 
 
X 
 
 
X 
 
X 
 
X 
HADS, ESS 
 
 
X 
 
 
X 
 
X 
X 
X 
ECG 
X 
 
 
 
X 
X 
 
X 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
 
 
 
 
 
 
 
Physical exam4 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Concomitant medications  
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Labs5  
X 
 
 
 
X 
 
  
X 
X 
X 
Urine pregnancy test6 
X 
 
X 
 
 
X 
 X 
X 
X 
X 
PK blood draw  
 
 
 
 
X 
X 
 
X 
 
 
Review of I/E criteria 
X 
X 
X 
 
 
 
 
 
 
 
IGA PN-A and IGA PN-S 
 
 
X 
 
X 
X 
 
X 
X 
X 
Photography (selected sites) 
 
 
X 
 
 
 
 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
 
 
 
  
 
 
 
X  
X 
eDiary review/compliance7 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispense and/or collect study drug 
 
 
X 
 
X 
X 
X 
X 
 
X 
Review study drug compliance 
 
 
 
 
X 
X 
X 
X 
 
 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
213

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 64 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
214

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 65 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1. 
boceprevir 
2. 
clarithromycin 
3. 
cobicistat 
4. 
conivaptan 
5. 
danoprevir and ritonavir 
6. 
diltiazem 
7. 
elvitegravir and ritonavir 
8. 
idelalisib 
9. 
indinavir and ritonavir 
10. 
itraconazolea 
11. 
ketoconazolea 
12. 
lopinavir and ritonavir 
13. 
nefazodone 
14. 
nelfinavir 
15. 
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir) 
16. 
posaconazolea 
17. 
ritonavir 
18. 
saquinavir and ritonavir 
19. 
telaprevir 
20. 
tipranavir and ritonavir 
21. 
troleandomycin 
22. 
voriconazolea 
23. 
regular grapefruit juice consumption (note: The effect of grapefruit juice varies 
widely among brands and is concentration-, dose-, and preparation-dependent. 
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the 
preparation)b 
 
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
 
215

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 66 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
216

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 67 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
217

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 68 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
218

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 69 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
219

Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 70 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
220